ArticleMicrobiology spectrum2026
Gut microbiota composition and tumor immune features in meningioma patients.
Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Meningiomas are prevalent intracranial tumors with poorly understood extraneural drivers. While the gut-brain axis influences neuro-oncogenesis, meningioma-specific gut microbiome alterations and their clinical implications remain uncharacterized. This study integrated 16S rRNA sequencing of fecal samples from 15 treatment-naïve WHO grade I meningioma patients (MPs) and 15 healthy controls (HCs) with immunohistochemical profiling of tumor immune infiltrates (MPO⁺ neutrophils, CD68⁺ macrophages, CD3⁺ T cells). Compared with HCs, MPs exhibited significantly reduced alpha diversity (Shannon index, IMPORTANCE: Detailed exploration of host-microbe interactions can be worthwhile. Gut dysbiosis has been implicated in neuroinflammation, blood-brain barrier disruption, and oncogenesis in multiple cancer types, including gliomas. However, the gut microbiota composition and metabolic characteristics in patients with meningioma have not been previously reported. To address these critical knowledge gaps, we conducted a case-control study integrating 16S rRNA sequencing, clinical phenotyping, and immunohistochemical profiling. Our study revealed significant alterations in the gut microbiota of MPs, characterized by reduced alpha diversity, enrichment of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.